Tolvaptan Can Improve Clinical Course in Responders-Reference-Cited by-同舟云学术

Tolvaptan Can Improve Clinical Course in Responders

Published:2013 Issue:6 Volume:54 Page:377-381
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Imamura Teruhiko¹,Kinugawa Koichiro²,Minatsuki Shun¹,Muraoka Hironori¹,Kato Naoko¹,Inaba Toshiro¹,Maki Hisataka¹,Hatano Masaru¹,Yao Atsushi¹,Komuro Issei¹

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

2. Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/54/6/54_377/_pdf

Reference17 articles.

1. 1. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25: S57-65.

2. 2. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: S33-45.

3. 3. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-61. (Review)

4. 4. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.

5. 5. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of tolvaptan on the prognosis of patients with hepatic ascites;Hepatology Research;2019-04-30

2. First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery;BMC Pediatrics;2019-02-12

3. Update of acute and long-term tolvaptan therapy;Journal of Cardiology;2019-02

4. Hemodilution after Initial Treatment in Patients with Acute Decompensated Heart Failure;International Heart Journal;2018-05-31

5. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics;International Heart Journal;2018